12 Article(s)
Pub. Date
#Total Relationship(s)
1 23726675 A phase 2, double-blind, randomized, placebo-controlled, dose-escalation study to evaluate the efficacy, safety, and tolerability of naloxegol in patients with opioid-induced constipation. Pain 2013 Sep 1
2 26248047 The effect of quinidine, a strong P-glycoprotein inhibitor, on the pharmacokinetics and central nervous system distribution of naloxegol. J Clin Pharmacol 2016 Apr 5
3 26317320 Population pharmacokinetics of naloxegol in a population of 1247 healthy subjects and patients. Br J Clin Pharmacol 2016 Jan 2
4 26535126 Efficacy and safety of naloxegol in patients with opioid-induced constipation and laxative-inadequate response. United European Gastroenterol J 2015 Oct 3
5 26678015 Effects of CYP3A Modulators on the Pharmacokinetics of Naloxegol. J Clin Pharmacol 2016 Aug 4
6 27137716 Safety, tolerability, and pharmacokinetics of multiple ascending doses of naloxegol. Clin Pharmacol Drug Dev 2015 Nov 1
7 27299937 Simulation and Prediction of the Drug-Drug Interaction Potential of Naloxegol by Physiologically Based Pharmacokinetic Modeling. CPT Pharmacometrics Syst Pharmacol 2016 May 5
8 27342744 Impact of Treatment with Naloxegol for Opioid-Induced Constipation on Patients' Health State Utility. Adv Ther 2016 Aug 2
9 27582887 The role of naloxegol in the management of opioid-induced bowel dysfunction. Therap Adv Gastroenterol 2016 Sep 2
10 28035588 Clinical Pharmacokinetics and Pharmacodynamics of Naloxegol, a Peripherally Acting µ-Opioid Receptor Antagonist. Clin Pharmacokinet 2017 Jun 1
11 28336575 Pharmacologic Profile of Naloxegol, a Peripherally Acting <i>µ</i>-Opioid Receptor Antagonist, for the Treatment of Opioid-Induced Constipation. J Pharmacol Exp Ther 2017 May 1
12 33030105 Molecular dynamics analysis predicts ritonavir and naloxegol strongly block the SARS-CoV-2 spike protein-hACE2 binding. J Biomol Struct Dyn 2022 Mar 3